Luminex Corporation (LMNX)
| Market Cap | 1.51B |
| Revenue (ttm) | 417.40M |
| Net Income (ttm) | 14.87M |
| Shares Out | 45.10M |
| EPS (ttm) | 0.33 |
| PE Ratio | 100.06 |
| Forward PE | n/a |
| Dividend | $0.37 |
| Dividend Yield | 1.14% |
| Trading Day | February 26 |
| Last Price | $32.52 |
| Previous Close | $32.99 |
| Change ($) | -0.47 |
| Change (%) | -1.42% |
| Day's Open | 32.58 |
| Day's Range | 30.88 - 32.90 |
| Day's Volume | 1,022,332 |
| 52-Week Range | 20.53 - 41.37 |
Luminex (LMNX) witnesses total sample-to-answer molecular diagnostics revenue growth in the fourth quarter.
Luminex (LMNX) delivered earnings and revenue surprises of -92.86% and 0.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Luminex (NASDAQ:LMNX) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 85.71% over the past year to $0.01, which missed t...
AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its fourth quarter and full-year ended December 31, 2020. All amounts in this release...
AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the first quarter of 2021...
AUSTIN, Texas, Jan. 13, 2021 /PRNewswire/ -- As previously announced, Luminex Corporation (Nasdaq: LMNX) will present at the 39th Annual J.P. Morgan Healthcare Conference, to be held virtually...
AUSTIN, Texas, Jan. 12, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 4th quarter 2020 revenue of approximately $111M, up approximately 23% over the 4th quarter of 20...
AUSTIN, Texas, Dec. 16, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that Nachum "Homi" Shamir, Chairman, CEO and President, and Harriss Currie, Senior Vice Presiden...
AUSTIN, Texas, Dec. 7, 2020 /PRNewswire/ -- On December 3, 2020, Luminex Corporation (Nasdaq:LMNX) (the "Company"), announced that its board of directors approved a $0.01 increase in the quart...
Luminex (LMNX) reported earnings 30 days ago. What's next for the stock?
These are the stocks seeing the most insider buying this week
Brian Sullivan on the top companies this week whose executives are purchasing their own stock, on Worldwide Exchange.
Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in the third quarter.
Luminex Corporation's (LMNX) CEO Homi Shamir on Q3 2020 Results - Earnings Call Transcript
Luminex (LMNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AUSTIN, Texas, Oct. 22, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the third quarter ended September 30, 2020 on Thursday, Nove...
AUSTIN, Texas, Oct. 7, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 3rd quarter 2020 revenues of approximately $106 million, up approximately 35% over the 3rd quarte...
You know what they say! To the most sensitive tests go the spoils.
Investor confidence is high on Luminex (LMNX) stock, thanks to solid prospects.
AUSTIN, Texas, Sept. 24, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received a $5,389,813 award from the Biomedical Advanced Research and Development A...
AUSTIN, Texas, Sept. 23, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received an award of $683,500 from the Biomedical Advanced Research and Development...
AUSTIN, Texas, Sept. 15, 2020 /PRNewswire/ -- On September 10, 2020, Luminex Corporation (Nasdaq:LMNX) (the "Company"), announced that its board of directors declared a cash dividend for the t...
Luminex (LMNX) reported earnings 30 days ago. What's next for the stock?
Blame it on Abbott.
Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in Q2
Luminex Corporation (LMNX) CEO Nachum Shamir on Q2 2020 Results- Earnings Call Transcript
Luminex (LMNX) delivered earnings and revenue surprises of 237.50% and -0.07%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Luminex sees its Relative Strength Rating reach the elite 90-plus level. The post Luminex Scores Relative Strength Rating Upgrade appeared first on Investor's Business Daily.
Shares of Luminex (NASDAQ:LMNX) moved higher by 6.77% in after-market trading after the company reported Q2 results.
AUSTIN, Texas, Aug. 4, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced the retirement of its Chairman, G.
Nate Pile — the editor of growth stock advisory Nate's Notes has just released the first issue of a new advisory service focused on retirement investing, The Little River Investment Guide. The...
AUSTIN, Texas, July 22, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted an EUA request to the FDA for a new expanded version of its NxTAG® Respira...
Luminex (LMNX) receives EUA for its xMAP SARS-CoV-2 Multi-Antigen IgG Assay, which can be used to rapidly detect the presence of antibodies in people affected by the virus causing COVID-19.
AUSTIN, Texas, July 20, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the second quarter ended June 30, 2020 on Tuesday, August 4,...
Shares of Luminex Corp. LMNX, +5.06% gained 10.8% in premarket trading on Monday after the company said its COVID-19 antibody test had received an emergency use authorization from the Food and...
AUSTIN, Texas, July 20, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for ...
Luminex (LMNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
AUSTIN, Texas, July 8, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 2nd quarter 2020 revenues of between $109 and $110 million, up more than 30% over the 2nd quarter...
Luminex (LMNX) commences rollout of new xMAP INTELLIFLEX Systems, which will expand its xMAP Technology.
AUSTIN, Texas, July 1, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the company has delivered the first of its new xMAP® INTELLIFLEX Systems to several of its L...
Luminex (LMNX) submits an EUA request to the FDA for its first multi-antigen IgG assay.
AUSTIN, Texas, June 29, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the company has submitted an Emergency Use Authorization request to the U.S. Food and Drug ...
These fast movers are currently witnessing a short-term pullback in price. So, this could essentially be a solid entry point for garnering better returns in the future.
Luminex (LMNX) reported earnings 30 days ago. What's next for the stock?
Luminex Corporation has been struggling lately, but the selling pressure may be coming to an end soon
Luminex (LMNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
AUSTIN, Texas, May 22, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the second quarter of 2...
Luminex (LMNX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
These fast movers are witnessing a short-term pullback in price as the COVID-19 pandemic dents investors' optimism. So, this could essentially be a great entry point for garnering better returns.
The company's convertible bond offering is causing shares to slide.
About LMNX
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module v... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Mar 30, 2000 |
| CEO Nachum Shamir | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol LMNX |
Analyst Forecasts
According to 5 analysts, the average rating for Luminex stock is "Hold." The 12-month stock price forecast is 33.50, which is an increase of 3.01% from the latest price.